AC Immune Stock Price, News & Analysis

AC Immune (NASDAQ: ACIU) reported Q3 2025 results and a corporate update on November 4, 2025. The company holds CHF 108.5 million in cash resources as of September 30, 2025 (CHF 27.7M cash and CHF 80.7M short-term assets) and said this provides funding to the end of Q3 2027 excluding milestone income. Management narrowed investment focus to three Phase 2 active immunotherapies and small-molecule programs (NLRP3, Tau, a-syn), reduced workforce by ~30%, and recognized CHF 0.5M restructuring expenses.

Near-term milestones expected in Q4 2025 include IND/CTA filing for ACI-19764, lead declarations and IND-enabling starts for Morphomer programs, and multiple Phase 1/2 readouts and interim Part 1 VacSYn results.

AC Immune (NASDAQ: ACIU) appointed Prof. Catherine Mummery as Chair of its Clinical Advisory Board effective October 28, 2025.

Prof. Mummery leads cognitive disorders at NHNN and novel therapeutics at UCL, has been senior investigator on more than 20 early-stage studies, led the first clinical trial of a Tau gene‑silencing therapy, and served as an investigator on AC Immune’s Phase 1b/2a ACI-35.030 (JNJ-2056) study.

The CAB advises on clinical development and regulatory strategy; other members include Reisa Sperling, Murat Emre, Lon Schneider, Pierre Tariot, and Juan Fortea. Dr. Kaj Blennow is retiring from the CAB.

AC Immune (NASDAQ: ACIU) announced that preclinical data for its first-in-class TDP-43 PET tracer ACI-19626 were published in Nature Communications (2025). The report shows high affinity and selectivity for pathological TDP-43 over Abeta, tau and alpha-synuclein, no off-target binding across a panel of >100 targets, and a non-human primate pharmacokinetic profile with rapid brain uptake and fast, complete washout. Based on these data, ACI-19626 advanced into a Phase 1 clinical trial with an initial readout expected in Q4 2025. The tracer aims to enable PET-based diagnosis and patient stratification for TDP-43 proteinopathies including ALS, FTD and LATE.

AC Immune (NASDAQ: ACIU) announced the peer-reviewed publication of Phase 1b/2a trial results for its anti-pTau active immunotherapy in eBioMedicine. The study compared two formulations: ACI-35.030 and JACI-35.054 in early Alzheimer's disease patients.

Key findings showed that ACI-35.030, developed using AC Immune's SupraAntigen® technology, demonstrated superior performance by generating rapid and potent polyclonal response against pathological Tau forms after a single dose. The treatment maintained 94-100% response rates through week 74 in high-dose cohorts, with no clinically relevant safety concerns.

Based on these positive results, ACI-35.030 has advanced to a potentially registration-enabling Phase 2b ReTain clinical trial in preclinical Alzheimer's disease, becoming the first active immunotherapy targeting Tau to be investigated in approximately 500 participants.

AC Immune (NASDAQ: ACIU) has announced a strategic restructuring to optimize its pipeline focus and extend its cash runway. The company will implement a 30% workforce reduction while concentrating on its three clinical-stage active immunotherapy programs and key small molecule programs targeting NLRP3 and Tau.

The restructuring will extend the company's cash runway through Q3 2027, supported by current cash resources of CHF 127.1 million as of June 30, 2025. The company maintains its clinical timeline guidance, with interim data expected from ACI-7104.056 in H2 2025 and ACI-24.060 in H1 2026.

The implementation will be completed by the end of 2025, with cost reductions becoming fully effective in early 2026. Affected employees will receive severance packages and support for new employment opportunities.

AC Immune (NASDAQ: ACIU) reported Q2 2025 financial results and provided updates on its neurodegenerative disease pipeline. The company maintains a strong financial position with CHF 127.1 million in cash, providing runway into Q1 2027. Key highlights include positive interim results from the Phase 2 VacSYn trial of ACI-7104.056 for Parkinson's disease, showing a 20-fold increase in anti-α-syn antibodies.

The company has three active immunotherapies in Phase 2 development, including ACI-24.060 for Alzheimer's disease, with interim results expected in early 2026. Their NLRP3 inhibitor program (ACI-19764) has advanced to IND-enabling studies. Q2 financial results showed contract revenues of CHF 1.3 million and a net loss of CHF 21.2 million, improved from CHF 22.8 million in Q2 2024.

AC Immune reported Q1 2025 financial results, highlighting strong progress in its neurodegenerative disease therapeutics pipeline. The company maintains a solid cash position of CHF 145.7 million, providing funding into Q1 2027.

Key developments include positive interim Phase 2 results for ACI-7104.056, their anti-alpha-synuclein immunotherapy for Parkinson's disease, showing strong immunogenicity and favorable safety. The treatment induced anti-a-syn antibodies over 20-fold higher than placebo levels after four immunizations.

Q1 2025 financials show R&D expenses of CHF 15.9 million (up from CHF 15.2 million in Q1 2024) and G&A expenses of CHF 4.4 million (down from CHF 5.0 million). The company reported a net loss of CHF 19.0 million, compared to CHF 17.9 million in the same period last year.

Multiple milestones are expected throughout 2025, including additional Phase 2 data readouts and potential trial initiations across their therapeutic portfolio.

AC Immune (NASDAQ: ACIU) has reported positive interim results from its Phase 2 VacSYn clinical trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease. The treatment has demonstrated significant efficacy, producing anti-α-synuclein antibody levels over 20-fold higher than placebo after 4 immunizations.

The trial's Part 1 involves over 30 patients randomized at a 3:1 ratio (treatment:placebo). Key findings show that antibody responses were effectively induced at week 6 after 2 immunizations and were further enhanced with additional doses. The treatment has shown a favorable safety profile with no serious adverse events reported, with only mild side effects including injection site reactions and headaches.

Based on upcoming interim results in 2025, including pharmacodynamic and biomarker data, the company may proceed with Part 2 of the trial, expanding to up to 150 patients. This phase will evaluate disease progression through motor and non-motor symptoms, along with digital, imaging, and fluid biomarkers.

AC Immune (NASDAQ: ACIU) has announced multiple presentations at the upcoming International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) in Vienna, Austria, from April 1-5, 2025. The company will host an industry symposium on April 2, focusing on active immunotherapies for neurodegenerative diseases.

The symposium will feature presentations on:

• Disease modification in Parkinson's disease
• ACI-7104.056 Phase 2 trial VacSYn
• ACI-35.030/JNJ2056 Phase 2b Retain study
• ACI-24.060 Phase 1b/2 ABATE study

Additional oral presentations will cover Morphomer® small molecules targeting Tau, Morphomer-antibody drug conjugates, and therapeutic molecules targeting alpha-synuclein aggregation. The event will include presentations from AC Immune leadership, key opinion leaders, and collaboration partners from Johnson & Johnson Innovative Medicine.